B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.

ABSTRACT:

Purpose

Multiple myeloma is a usually incurable malignancy of plasma cells. New therapies are urgently needed for multiple myeloma. Adoptive transfer of chimeric antigen receptor (CAR)-expressing T cells is a promising new therapy for hematologic malignancies, but an ideal target antigen for CAR-expressing T-cell therapies for multiple myeloma has not been identified. B-cell maturation antigen (BCMA) is a protein that has been reported to be selectively expressed by B-lineage cells including multiple myeloma cells. Our goal was to determine if BCMA is a suitable target for CAR-expressing T cells.

Experimental design

We conducted an assessment of BCMA expression in normal human tissues and multiple myeloma cells by flow cytometry, quantitative PCR, and immunohistochemistry. W

SUBMITTER: Carpenter RO 

PROVIDER: S-EPMC3630268 | biostudies-literature | 2013 Apr

REPOSITORIES: biostudies-literature